Moderna, Inc. (MRNA): Price and Financial Metrics
Moderna, Inc. (MRNA)
Today's Latest Price: $129.65 USD
Updated Jan 15 4:00pm
Add MRNA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
MRNA Stock Summary
- MRNA's price/sales ratio is 208.07; that's higher than the P/S ratio of 97.86% of US stocks.
- With a year-over-year growth in debt of 514.07%, Moderna Inc's debt growth rate surpasses 96.56% of about US stocks.
- Revenue growth over the past 12 months for Moderna Inc comes in at 202.43%, a number that bests 96.95% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Moderna Inc are VRTX, BGNE, REGN, BNTX, and MRVL.
- Visit MRNA's SEC page to see the company's official filings. To visit the company's web site, go to www.modernatx.com.
MRNA Stock Price Chart Interactive Chart >
MRNA Price/Volume Stats
| Current price | $129.65 | 52-week high | $178.50 |
| Prev. close | $129.72 | 52-week low | $17.91 |
| Day low | $126.58 | Volume | 15,769,500 |
| Day high | $133.29 | Avg. volume | 16,786,420 |
| 50-day MA | $119.03 | Dividend yield | N/A |
| 200-day MA | $77.74 | Market Cap | 51.30B |
Moderna, Inc. (MRNA) Company Bio
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA
Loading social stream, please wait...